New pill vs chemotherapy for advanced pancreatic cancer with KRAS G12D gene
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial compares a new targeted pill (DN022150) with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12D gene change. It aims to see if the new drug works better at shrinking tumors and improving survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your pancreatic cancer has a specific gene change called KRAS G12D.
- You have already received previous treatment for advanced or metastatic pancreatic cancer.
- You are able to take care of yourself (ECOG score 0 or 1), meaning you are mostly up and about.
- You have at least one tumor that can be measured by imaging scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (DN022150) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The combination may help shrink or slow the cancer better than chemotherapy alone.
This trial tests three new targeted drug combinations for pancreatic cancer that has a specific genetic change (KRAS G12D). They are comparing the study drug alone versus combining it with other investigational drugs to see which works better.
This trial tests two new targeted pills (zoldonrasib and daraxonrasib) compared to the standard chemotherapy (gemcitabine and nab-paclitaxel) as the first treatment for metastatic pancreatic cancer with a specific KRAS G12D mutation. The new pills may specifically attack cancer cells with this mutation.
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
This trial tests a new treatment called QLS31905 plus chemotherapy against a placebo plus chemotherapy for people with advanced pancreatic cancer that hasn't been treated yet. It aims to see if the new combination works better.
This study tests a new targeted drug, GFH375, against standard chemotherapy for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the new drug works better and has fewer side effects.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.